BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21852010)

  • 1. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial.
    Wang J; Shi M; Ling R; Xia Y; Luo S; Fu X; Xiao F; Li J; Long X; Wang J; Hou Z; Chen Y; Zhou B; Xu M
    Radiother Oncol; 2011 Aug; 100(2):200-4. PubMed ID: 21852010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
    Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
    Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients.
    Königsberg R; Pfeiler G; Kurzawa R; Hudec M; Zeillinger R; Dittrich C; Singer C
    Cancer Invest; 2011 Feb; 29(2):180-6. PubMed ID: 21261479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
    Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
    Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
    Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
    Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of triple negative phenotype in conservatively treated breast cancer.
    Barbieri V; Sanpaolo P; Genovesi D
    Breast J; 2011; 17(4):377-82. PubMed ID: 21615820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes.
    Wright JL; Cordeiro PG; Ben-Porat L; Van Zee KJ; Hudis C; Beal K; McCormick B
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):43-50. PubMed ID: 17855006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
    Kennedy CR; Gao F; Margenthaler JA
    J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases].
    Yuan ZY; Wang SS; Gao Y; Su ZY; Luo WB; Guan ZZ
    Ai Zheng; 2008 Jun; 27(6):561-5. PubMed ID: 18570725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG; Malmgren JA; Atwood M
    Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
    Stemmer SM; Rizel S; Hardan I; Adamo A; Neumann A; Goffman J; Brenner HJ; Pfeffer MR
    J Clin Oncol; 2003 Jul; 21(14):2713-8. PubMed ID: 12860949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.